CytoDyn
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, CytoDyn sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).
CytoDyn: 18 sponsored US clinical trials, 1 recruiting.
CytoDyn sponsors 18 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 13 completed. 0 of these trials are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Coronavirus Disease 2019, with 2 trials.
Top-decile sponsor footprint
CytoDyn ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
18 total, page 1 of 1
A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC
NCT06699836
Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
NCT04678830
Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis
NCT04521114
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
NCT04504942
Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
NCT04347239
Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19
NCT04343651
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
NCT03838367
PRO 140 in Treatment-Experienced HIV-1 Subjects
NCT03902522
An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study
NCT05271370
A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation
NCT02737306
Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection
NCT02859961
Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140
NCT02483078
An Extension of Protocol PRO 140_CD01 Study
NCT02355184
Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
NCT02175680
Observational Study of Blood Treated With Cytolin
NCT01048372
Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection
NCT00642707
PRO 140 by IV Administration in Adults With HIV-1 Infection
NCT00613379
Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers
NCT00110591
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 15 |
Therapeutic Areas
What is open in the CytoDyn pipeline
1 recruiting of 18 indexed (6% open); 13 completed (72%).
Phase mix: 0 late (III/IV) vs 17 early (I/II) (early-phase heavy).
Top condition: Coronavirus Disease 2019 (2 trials), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
CytoDyn: open-pipeline peers nationwide
Peers matched on 18 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
CytoDyn sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 18 trials (± recruiting share)
- ADC Therapeutics S.A. · 18 trials · 11% recruiting
- Akros Pharma · 18 trials · 0% recruiting
- AO Clinical Investigation and Publishing Documentation · 18 trials · 0% recruiting
- AO Innovation Translation Center · 18 trials · 33% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Boston College · 6% recruiting · 18 trials
- Dendreon · 6% recruiting · 18 trials
- Intercept Pharmaceuticals · 6% recruiting · 18 trials
- NGM Biopharmaceuticals · 6% recruiting · 18 trials
Related
What to do with this CytoDyn page
18 registered trials is a research-attention snapshot, not an endorsement of CytoDyn or any single study.
- 1 of CytoDyn's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Coronavirus Disease 2019 is the condition CytoDyn studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Coronavirus Disease 2019 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
CytoDyn pipeline card: 18 registered trials from official public datasets.Report a data error.